Omnilux™ was originally developed at the Paterson Institute for Cancer Research. Its optimized intensity and adjustable dose function have been used in the treatment of thousands of non-melanoma lesions. It is especially effective in cosmetically sensitive areas and for lesions in poor healing sites. Compared with conventional modalities, treatment outcomes are excellent, with significantly fewer adverse events.[1]
Specifically, the use of Omnilux along with ALA-PDT has been shown to be optimally effective in treating:
Omnilux PDT™ offers the advantages of being non-invasive and well tolerated in slow healing sites; the treatment also spares tissues leaving the skin surrounding the tumor intact and functional, with good cosmesis.[1]
C A Morton MBCh,
MRCP Falkirk, Scotland
